Evaluation of Quality of Life Using EORTC QLQ‐BM22 in Patients with Bone Metastases after Treatment with Magnetic Resonance Guided Focused Ultrasound

Chen, Zhengqi; Wang, Chongren; Ma, Xiao‐Jun; Sun, Wei; Shen, Junhao; Sun, Mengxiong; Fu, Zeze; Hua, Yingqi; Cai, Zhengdong

doi:10.1111/os.12383

Cited by 5 publications

(7 citation statements)

References 27 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies used the QLQ-BM22 subscale scores to evaluate the survival quality of patients with bone metastases ( 19 , 41 ). QLQ-BM22 included functional interference, psychosocial aspects, painful site, and pain characteristics.…”

Section: Resultsmentioning

confidence: 99%

“…As time went by, the scores gradually increased. In addition, two studies used QLQ-C15 ( 19 , 41 ), one study used QLQ-C30 ( 40 ), one study used biomarker evaluation including alkaline phosphatase and lactic acid dehydrogenase ( 22 ), and one study used median overall survival time ( 13 ). All abovementioned indicators showed good therapeutic effects with the treatment of MRgFUS.…”

Section: Resultsmentioning

confidence: 99%

“…It delivers acoustic energy to heat the lesion in an ablation temperature (over 65°C) locally and subsequently induces local tumor tissue coagulation and necrosis. In addition, it also destroys the nerve on the affected periosteum, which alleviates cancer pain in both osteoblasts and osteolytic bone metastases (17)(18)(19). MRI-guided focused ultrasound (MRgFUS) therapy is a novel focused ultrasound method, which enables oncologists to perform ablation precisely and provides real-time temperature monitoring by MR thermometers (20,21).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Roles of Magnetic Resonance-Guided Focused Ultrasound in Pain Relief in Patients With Bone Metastases: A Systemic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

ObjectiveCancer pain, the most common skeleton-related event of bone metastases, significantly disturbs patients’ life. MRI-guided focused ultrasound (MRgFUS) is a therapeutic option to relieve pain; however, its efficacy and safety have not been fully explored. Therefore, we aim to conduct a meta-analysis on studies reporting MRgFUS for patients with bone metastases.MethodsRandomized controlled trials (RCT) and non-RCTs on MRgFUS treatment for patients with bone metastases were collected using PubMed, MEDLINE In-Process (US National Library of Medicine), National Institutes of Health (US National Library of Medicine), Embase (Elsevier), Web of Science, CINAHL, and the Cochrane Library between August 2007 and September 2019. Data on quantitative pain assessment before/after MRgFUS, response rate, and complication were extracted and analyzed.ResultsFifteen eligible studies with 362 patients were selected in this meta-analysis. The average pain score was 6.74 (95% CI: 6.30–7.18) at baseline, 4.15 (95% CI: 3.31–4.99) at 0–1 week, 3.09 (95% CI: 2.46–3.72) at 1–5 weeks, and 2.28 (95% CI: 1.37–3.19) at 5–14 weeks. Compared with baseline, the pain improvement at 0–1 week was 2.54 (95% CI: 1.92–3.16, p < 0.01), at 1–5 weeks was 3.56 (95% CI: 3.11–4.02, p < 0.01), and at 5–14 weeks was 4.22 (95% CI: 3.68–4.76, p < 0.01). Change from baseline in OMEDD at 2 weeks after treatment was −15.11 (95% CI: −34.73, 4.50), at 1 month after treatment was −10.87 (95% CI: −26.32, 4.58), and at 3 months after treatment was −5.53 (95% CI: −20.44, 9.38). The overall CR rate was 0.36 (95% CI: 0.24–0.48), PR rate was 0.47 (95% CI: 0.36–0.58), and NR rate was 0.23 (95% CI: 0.13–0.34). Among 14 studies including 352 patients, 93 (26.4%) patients with minor complications and 5 (1.42%) patients with major complications were recorded.ConclusionThis meta-analysis identifies MRgFUS as a reliable therapeutic option to relieve cancer pain for patients with metastatic bone tumors with controllable related complications.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Roles of Magnetic Resonance-Guided Focused Ultrasound in Pain Relief in Patients With Bone Metastases: A Systemic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a retrospective study enrolling 26 patients receiving US-HIFU treatments, the mean VAS pain scores changed from 6.69 ± 1.44 at baseline to 5.96 ± 1.14 at 12 months post treatments. Albeit a 10.9% reduction in pain score, the difference was significant (p value < 0.01) [22]. The 1-, 2-, 3-, and 5-year survival rates of 12 patients undergoing US-HIFU treatments were 83.3%, 16.7%, 0%, and 0%, respectively [23].…”

Section: Treatment Of Bone Metastasismentioning

confidence: 87%

“…Concurrent with pain palliation, patients who underwent HIFU treatments also experienced improvement in quality of life (QoL) and reduction in analgesic intake. QoL has been assessed using different questionnaires, such as the brief pain inventory (BPI) QoL [15,20,24,25], the European Organization for Research and Treatment of Cancer (EORTC)'s Quality of Life Questionnaire Core 15 Palliative Care (QLQ-C15-PAL) [26,27], and the EORTC QoL Questionnaires for Patients with Bone Metastases 22 (EORTC QLQ-BM22) [22,26,28], or EORTC QLQ-C30 [18]. As presented by Hurwitz et al in a randomized controlled trial (RCT), the BPI-QoL score at 3 months after MR-HIFU therapy was 2.4 points better than the placebo arm [15].…”

Section: Treatment Of Bone Metastasismentioning

confidence: 99%

High Intensity Focused Ultrasound for Treatment of Bone Malignancies—20 Years of History

Yeo

Bratke

Grüll

2022

Cancers

View full text Add to dashboard Cite

High Intensity Focused Ultrasound (HIFU) is the only non-invasive method for percutaneous thermal ablation of tissue, with treatments typically performed either under magnetic resonance imaging or ultrasound guidance. Since this method allows efficient heating of bony structures, it has found not only early use in treatment of bone pain, but also in local treatment of malignant bone tumors. This review of 20 years of published studies shows that HIFU is a very efficient method for rapid pain relief, can provide local tumor control and has a very patient-friendly safety profile.

show abstract

Efficacy and safety of magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objective To report the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) in the treatment of painful bone metastases through a systematic review and meta-analysis of pain scores before and after MRgFUS treatment and post-treatment adverse events. Materials and methods A comprehensive literature search of PubMed and Embase databases was performed for studies evaluating the efficacy and/or safety of MRgFUS. The mean difference of pain scores (10-point visual analogue scale or numerical rating scale) between baseline and 1-month/3-month pain scores was collected and analyzed in a pooled meta-analysis. Post-treatment adverse events based on the Common Terminology Criteria for Adverse Events (CTCAE) grading were recorded and the pooled prevalence was calculated. Results A total of 33 studies published between 2007 and 2019 were collected, resulting in a total sample size of 1082 patients. The majority of the studies were prospective with a reported follow-up period of 3 months. The pooled proportion of patients that achieved pain relief from MRgFUS (complete response or partial response [≥ 2-point improvement of pain score]) was 79% (95% CI 73–83%). The pooled 1-month and 3-month mean difference in pain score were − 3.8 (95% CI − 4.3; − 3.3) and − 4.4 (95% CI − 5.0; − 3.7), respectively. The overall rate of high-grade (CTCAE grade 3 or higher) and low-grade (CTCAE grade 2 or lower) MRgFUS-related adverse events were 0.9% and 5.9%, respectively. Conclusion MRgFUS is an effective procedure that is able to provide significant pain palliation for patients with symptomatic bone metastases with a favorable safety profile.

show abstract

Evaluation of Quality of Life Using EORTC QLQ‐BM22 in Patients with Bone Metastases after Treatment with Magnetic Resonance Guided Focused Ultrasound

Abstract: MRgFUS therapy improved the QOL of patients with bone metastasis by relieving bone pain.

Cited by 5 publications

References 27 publications

The Roles of Magnetic Resonance-Guided Focused Ultrasound in Pain Relief in Patients With Bone Metastases: A Systemic Review and Meta-Analysis

The Roles of Magnetic Resonance-Guided Focused Ultrasound in Pain Relief in Patients With Bone Metastases: A Systemic Review and Meta-Analysis

High Intensity Focused Ultrasound for Treatment of Bone Malignancies—20 Years of History

Efficacy and safety of magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: a systematic review and meta-analysis

Contact Info

Product

Resources

About